Delve Bio
1 known investors
Delve develops Delve Detect, a metagenomic sequencing (mNGS) test that identifies bacteria, viruses, fungi, and parasites in cerebrospinal fluid to diagnose meningitis and encephalitis. The test is aimed at clinical diagnostics, reporting higher diagnostic yield and results within 48 hours of sample receipt.
BiotechHealthtechMedical Devices
Investors · 1
Frequently asked questions
- What does Delve Bio do?
- Delve develops Delve Detect, a metagenomic sequencing (mNGS) test that identifies bacteria, viruses, fungi, and parasites in cerebrospinal fluid to diagnose meningitis and encephalitis. The test is aimed at clinical diagnostics, reporting higher diagnostic yield and results within 48 hours of sample receipt.
- Who are Delve Bio's investors?
- Delve Bio's investors include GV (Google Ventures).